J. Doroshow

J. Doroshow, W. Ye, L. Leong, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reactivity of plasma glutathione peroxidase with hydroperoxide substrates and glutathione.

J. Doroshow, A. Girotti, F. Chu, 1993, Archives of biochemistry and biophysics.

Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.

J. Doroshow, L. Leong, G. Somlo, 2000, Gynecologic oncology.

Dose-Escalating and Pharmacologic Study of Oxaliplatin in Adult Cancer Patients with Impaired Hepatic Function: A National Cancer Institute Organ Dysfunction Working Group Study

J. Doroshow, D. Gandara, C. Takimoto, 2007, Clinical Cancer Research.

High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.

J. Doroshow, L. Leong, S. Akman, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phospholipid hydroperoxide glutathione peroxidase is the 18-kDa selenoprotein expressed in human tumor cell lines.

J. Doroshow, K. Davies, F. Ursini, 1991, The Journal of biological chemistry.

Results of a prospective randomized trial of continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries

J. Doroshow, J. Beatty, M. Kemeny, 1986, Cancer.

Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors

L. Rubinstein, J. Doroshow, A. Chen, 2021, Investigational New Drugs.

Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.

R. Fisher, M. Atkins, J. Sosman, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

The Partnership for Accelerating Cancer Therapies

F. Collins, L. Tabak, D. Lowy, 2018, Cancer journal.

Dual oxidase 2 and pancreatic adenocarcinoma: IFN-γ-mediated dual oxidase 2 overexpression results in H2O2-induced, ERK-associated up-regulation of HIF-1α and VEGF-A

Han Liu, J. Doroshow, M. Hollingshead, 2016, Oncotarget.

Development of a quantitative pharmacodynamic assay for apoptosis in fixed tumor tissue and its application in distinguishing cytotoxic drug—induced DNA double strand breaks from DNA double strand breaks associated with apoptosis

J. Doroshow, R. Parchment, M. Hollingshead, 2018, Oncotarget.

A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer

J. Doroshow, J. Bennett, C. Vogel, 1985, Investigational New Drugs.

Copper ion-mediated modification of bases in DNA in vitro by benzoyl peroxide.

J. Doroshow, S. Akman, T. Kensler, 1993, Carcinogenesis.

HER‐2/neu is overexpressed infrequently in patients with prostate carcinoma

J. Doroshow, D. Gandara, P. Gumerlock, 2002, Cancer.

The effect of doxorubicin on hepatic and cardiac glutathione.

J. Doroshow, G. Locker, C. Myers, 1979, Research communications in chemical pathology and pharmacology.

Expression of plasma glutathione peroxidase in human liver in addition to kidney, heart, lung, and breast in humans and rodents.

J. Doroshow, F. Chu, X. F. Liu, 1992, Blood.

Characterization of NADPH oxidase 5 expression in human tumors and tumor cell lines with a novel mouse monoclonal antibody.

Han Liu, J. Doroshow, S. Hewitt, 2013, Free radical biology & medicine.

Defects in Nicotinamide-adenine Dinucleotide Phosphate Oxidase Genes NOX1 and DUOX2 in Very Early Onset Inflammatory Bowel Disease

Judy H. Cho, M. Silverberg, A. Griffiths, 2015, Cellular and molecular gastroenterology and hepatology.

Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor

E. Sausville, J. Doroshow, B. Conley, 2006, Cancer Chemotherapy and Pharmacology.

Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.

J. Doroshow, A. Chen, S. Kummar, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group.

J. Doroshow, D. Gandara, C. Takimoto, 2003, Seminars in oncology.

Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group.

J. Doroshow, C. Takimoto, J. Grem, 2003, Seminars in oncology.

Cisplatin dose intensity in non-small cell lung cancer: phase II results of a day 1 and day 8 high-dose regimen.

E. Perez, J. Hannigan, J. Doroshow, 1989, Journal of the National Cancer Institute.

Glutathione peroxidase and oxidative stress.

J. Doroshow, 1995, Toxicology letters.

Mitomycin C-enhanced superoxide and hydrogen peroxide formation in rat heart.

J. Doroshow, 1981, The Journal of pharmacology and experimental therapeutics.

Resistance to hydrogen peroxide associated with altered catalase mRNA stability in MCF7 breast cancer cells.

J. Doroshow, S. Akman, F. Chu, 1989, Biochimica et biophysica acta.

Phase I trial of carboplatin and infusional cyclosporin in advanced malignancy.

J. Doroshow, L. Leong, S. Akman, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study.

J. Doroshow, M. Sznol, J. Abrams, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The promise of antibody-drug conjugates.

J. Doroshow, B. Teicher, 2012, The New England journal of medicine.

High‐dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high‐risk primary breast cancer

J. Doroshow, L. Leong, S. Akman, 1994, Cancer.

Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.

R. Fisher, M. Atkins, J. Sosman, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials.

J. Buckner, E. Korn, G. Hortobagyi, 2013, Journal of the National Cancer Institute.

Ultrastructural features of Adriamycin-induced skeletal and cardiac muscle toxicity.

J. Doroshow, J. Schechter, C. Tallent, 1985, The American journal of pathology.

Development and Validation of an Immunoassay for Quantification of Topoisomerase I in Solid Tumor Tissues

Yvonne A. Evrard, Y. Pommier, J. Doroshow, 2012, PloS one.

Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.

R. Fisher, M. Atkins, J. Doroshow, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neurophysiological Study of Peripheral Neuropathy after High-Dose Paclitaxel

J. Doroshow, G. Somlo, S. Forman, 2004, Clinical Cancer Research.

A phase II study of BAY 43-9006 (Sorafenib) in patients with relapsed non-small cell lung cancer (NSCLC).

P. Choyke, J. Doroshow, J. Wright, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Characterization of potent and selective iodonium-class inhibitors of NADPH oxidases.

A. Monks, J. Doroshow, Smitha Antony, 2017, Biochemical pharmacology.

Functional activity and tumor-specific expression of dual oxidase 2 in pancreatic cancer cells and human malignancies characterized with a novel monoclonal antibody

Han Liu, J. Doroshow, S. Hewitt, 2013, International journal of oncology.

First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.

M. A. Mahr, Minetta C. Liu, D. Visscher, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dexamethasone Inhibits Cytokine-Induced, DUOX2-Related VEGF-A Expression and DNA damage in Human Pancreatic Cancer Cells and Growth of Pancreatic Cancer Xenografts

J. Doroshow, Smitha Antony, K. Roy, 2022, bioRxiv.

Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors

Y. Yen, J. Doroshow, L. Leong, 1996, Cancer Chemotherapy and Pharmacology.

Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.

R. Fisher, C. Coltman, J. Doroshow, 1988, Annals of internal medicine.

A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.

M. Atkins, J. Doroshow, G. Weiss, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Trial of Intraperitoneal Gemcitabine in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity

Y. Yen, J. Doroshow, L. Leong, 2007, Clinical Cancer Research.

Technical aspects of intraperitoneal chemotherapy in abdominal carcinomatosis.

J. Doroshow, P. Braly, S. Hoff, 1986, Gynecologic oncology.

A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer

M. Fishman, Y. Yen, J. Doroshow, 2004, Cancer Chemotherapy and Pharmacology.

Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors

Y. Pommier, L. Rubinstein, J. Doroshow, 2016, Cancer Chemotherapy and Pharmacology.

Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels.

J. Doroshow, L. Leong, S. Akman, 1995, Gynecologic oncology.

Pharmacokinetics of diastereoisomers of (6R,S)-folinic acid (leucovorin) in humans during constant high-dose intravenous infusion.

J. Doroshow, J. Straw, E. Newman, 1989, Cancer research.

High‐dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high‐risk primary breast cancer

J. Doroshow, L. Leong, S. Akman, 1994, Cancer.

Phase I study of mitomycin C and menadione in advanced solid tumors

J. Doroshow, L. Leong, S. Akman, 1995, Cancer Chemotherapy and Pharmacology.

Effect of low-dose prophylactic dopamine on high-dose cisplatin-induced electrolyte wasting, ototoxicity, and epidermal growth factor excretion: a randomized, placebo-controlled, double-blind trial.

J. Doroshow, L. Leong, G. Somlo, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics.

Y. Yen, J. Doroshow, L. Leong, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial

J. Doroshow, D. Gandara, H. Lenz, 2015, Cancer Chemotherapy and Pharmacology.

Treatment of metastatic malignant melanoma with trimetrexate: a phase II study.

J. Doroshow, L. Leong, S. Akman, 1990, Medical and pediatric oncology.

Failure of pretreatment with intravenous folic acid to alter the cumulative hematologic toxicity of lometrexol.

S. Groshen, J. Doroshow, F. Muggia, 1996, Journal of the National Cancer Institute.

Copper-dependent site-specific mutagenesis by benzoyl peroxide in the supF gene of the mutation reporter plasmid pS189.

J. Doroshow, S. Akman, T. Kensler, 1992, Carcinogenesis.

Pharmacological characterization of the seven human NOX isoforms and their inhibitors

K. Krause, J. Doroshow, R. Stocker, 2019, Redox biology.

Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies [published erratum appears in Blood 1987 Jun;69(6):1789]

J. Doroshow, J. Fahey, S. Forman, 1987 .

The Cyclin-Dependent Kinase Inhibitor UCN-01 Plus Cisplatin in Advanced Solid Tumors: A California Cancer Consortium Phase I Pharmacokinetic and Molecular Correlative Trial

J. Doroshow, D. Gandara, P. Gumerlock, 2005, Clinical Cancer Research.

Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma: a phase II trial.

J. Doroshow, L. Leong, S. Akman, 1999, Cancer investigation.

Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial

E. Perez, J. Doroshow, V. Israel, 2001, Cancer Chemotherapy and Pharmacology.

Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute

C. Flowers, L. Rubinstein, J. Doroshow, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and correlative science trial of UCN-01 plus cisplatin (CDDP) in advanced solid tumors: A California Cancer Consortium study.

J. Doroshow, D. Gandara, P. Gumerlock, 2004, Journal of Clinical Oncology.

Oral and intravenous pharmacokinetics of 5-fluoro-2′-deoxycytidine and THU in cynomolgus monkeys and humans

J. Doroshow, S. Kummar, Myrtle A. Davis, 2015, Cancer Chemotherapy and Pharmacology.

HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.

P. Meltzer, J. Trent, J. Doroshow, 1990, Journal of the National Cancer Institute.

Mechanisms of Anthracycline-Enhanced Reactive Oxygen Metabolism in Tumor Cells

J. Doroshow, 2019, Oxidative medicine and cellular longevity.

Mitomycin C and menadione for the treatment of advanced gastrointestinal cancers: a phase II trial

J. Doroshow, L. Leong, S. Akman, 1995, Journal of Cancer Research and Clinical Oncology.

Mitomycin C and menadione for the treatment of lung cancer: a phase II trial

J. Doroshow, L. Leong, S. Akman, 2004, Investigational New Drugs.

Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency Perspective.

K. Flaherty, A. Ribas, J. Doroshow, 2021, Cancer discovery.

Initial reporting from the prospective National Cancer Institute (NCI) COVID-19 in Cancer Patients Study (NCCAPS).

S. Chanock, M. Knopp, W. McCaskill-Stevens, 2021 .

A study of radiotherapy modalities combined with continuous 5-FU infusion for locally advanced gastrointestinal malignancies.

Y. Yen, J. Doroshow, L. Leong, 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function

J. Doroshow, C. Takimoto, J. Grem, 2007, Clinical Cancer Research.

A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma.

R. Fisher, J. Doroshow, G. Weiss, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mapping of Copper/Hydrogen Peroxide-induced DNA Damage at Nucleotide Resolution in Human Genomic DNA by Ligation-mediated Polymerase Chain Reaction (*)

J. Doroshow, R. Drouin, G. Holmquist, 1995, The Journal of Biological Chemistry.

Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis.

Y. Yen, J. Doroshow, L. Leong, 1998, Cancer research.

The Cyclin-Dependent Kinase Inhibitor UCN-01 Plus Cisplatin in Advanced SolidTumors : ACalifornia Cancer Consortium Phase I Pharmacokinetic andMolecular Correlative Trial

J. Doroshow, D. Gandara, P. Gumerlock, 2005 .

Phase I study of CT-2106 (polyglutamate camptothecin) in patients with advanced malignancies.

J. Doroshow, C. Takimoto, J. Dupont, 2004, Journal of Clinical Oncology.

Ocular irritation from high‐dose methotrexate therapy: Pharmacokinetics of drug in the tear film

J. Doroshow, D. Gaasterland, G. Locker, 1981, Cancer.

Effects of iodonium-class flavin dehydrogenase inhibitors on growth, reactive oxygen production, cell cycle progression, NADPH oxidase 1 levels, and gene expression in human colon cancer cells and xenografts.

J. Doroshow, S. Gaur, Xiwei Wu, 2013, Free radical biology & medicine.

Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer

J. Doroshow, M. Edelman, F. Meyers, 2004, Investigational New Drugs.

A pan-cancer PDX histology image repository with genomic and pathological annotations for deep learning analysis

Steven B. Neuhauser, Yvonne A. Evrard, Jeffrey H. Chuang, 2022, bioRxiv.

High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome

Y. Yen, J. Doroshow, L. Leong, 2001, British Journal of Cancer.

Modification of DNA bases in chromatin of intact target human cells by activated human polymorphonuclear leukocytes.

J. Doroshow, S. Akman, M. Dizdaroglu, 1993, Cancer research.

High-dose continuous infusion folinic acid and bolus 5-fluorouracil in patients with advanced colorectal cancer: a phase II study.

J. Doroshow, L. Leong, B. Carr, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: A California Cancer Consortium trial

J. Doroshow, D. Gandara, H. Lenz, 2005 .

Commentary: publishing cancer clinical trial results: a scientific and ethical imperative.

J. Doroshow, 2008, The oncologist.

3'-[18F]fluoro-3'-deoxythymidine ([18F]FLT) Positron Emission Tomography as an In Vivo Biomarker of inhibition of CDK 4/6-Rb pathway by Palbociclib in a patient derived bladder tumor

J. Doroshow, M. Hollingshead, J. Tatum, 2022, Journal of translational medicine.

High‐risk germ cell tumors in men high response rate and severe toxicity with cisplatin, vinblastine, bleomycin, and etoposide

J. Doroshow, D. Blayney, K. Margolin, 1993, Cancer.

Cloning and sequencing of the cDNA encoding a human testis phospholipid hydroperoxide glutathione peroxidase.

J. Doroshow, R. Esworthy, F. Chu, 1994, Gene.

Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) administered twice weekly

J. Doroshow, B. Conley, S. Kummar, 2007 .

Hepatic chemoembolization combined with systemic infusion of 5‐fluorouracil and bolus leucovorin for patients with metastatic colorectal carcinoma

J. Doroshow, M. Zalupski, C. Leichman, 1999, Cancer.

Role of Reactive Oxygen Species in the Cytotoxicity of Arsenic Trioxide and Pamidronate for Human Prostate Cancer Cells.

J. Doroshow, S. Gaur, 2020, Reactive oxygen species.

Transforming the Early Drug Development Paradigm at the National Cancer Institute: The Formation of NCI's Experimental Therapeutics Clinical Trials Network (ETCTN)

J. Doroshow, J. Abrams, A. Gravell, 2019, Clinical Cancer Research.

Effect of Anticancer Quinones on Reactive Oxygen Production by Adult Rat Heart Myocytes

J. Doroshow, 2020, Oxidative medicine and cellular longevity.

A California Cancer Consortium phase II trial of concurrent twice-weekly paclitaxel, weekly carboplatin and radiation followed by paclitaxel/carboplatin consolidation for stage III non-small-cell lung cancer

J. Doroshow, V. Israel, D. Gandara, 2000 .

Characterization and partial amino acid sequence of human plasma glutathione peroxidase.

J. Doroshow, R. Paxton, S. Akman, 1991, Archives of biochemistry and biophysics.

Effect of doxorubicin-enhanced hydrogen peroxide and hydroxyl radical formation on calcium sequestration by cardiac sarcoplasmic reticulum.

J. Doroshow, R. N. Harris, 1985, Biochemical and biophysical research communications.

Dexrazoxane for the prevention of cardiac toxicity and treatment of extravasation injury from the anthracycline antibiotics.

J. Doroshow, 2012, Current pharmaceutical biotechnology.

Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma.

R. Fisher, J. Sosman, J. Doroshow, 1997, Clinical Cancer Research.

Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study

R. Schilsky, M. Ratain, J. Doroshow, 2004, Cancer Chemotherapy and Pharmacology.

Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial

Y. Yen, J. Doroshow, D. Gandara, 2002, Cancer Chemotherapy and Pharmacology.

Abstract 3616: Validation and fitness testing of a quantitative immunoassay for HIF1α in biopsy specimens

J. Doroshow, R. Parchment, M. Hollingshead, 2012 .

Induction of a human carbonyl reductase gene located on chromosome 21.

T. Mohandas, J. Doroshow, R. Paxton, 1990, Biochimica et biophysica acta.

Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.

J. Doroshow, L. Leong, G. Somlo, 1999, Gynecologic oncology.

The Clinical Features of Hepatic Angiosarcoma: A Report of Four Cases and A Review of the English Literature

J. Doroshow, L. Zwelling, B. Chabner, 1979, Medicine.

Survey of the provision of supportive care services at National Cancer Institute-designated cancer centers.

L. Rivera, J. Doroshow, B. Ferrell, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biliary colic heralding systemic relapse in non‐hodgkin lymphoma

J. Doroshow, C. Myers, T. Anderson, 1980, Journal of surgical oncology.

Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.

J. Doroshow, L. Leong, G. Somlo, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of merbarone in soft tissue sarcoma

J. Doroshow, E. Kraut, S. Balcerzak, 1992, Investigational New Drugs.

Analysis of Glutathione‐Related Enzymes

J. Doroshow, R. Esworthy, F. Chu, 1999, Current protocols in toxicology.

Genomic sequence and expression of a cloned human carbonyl reductase gene with daunorubicin reductase activity.

J. Doroshow, W. D. Kaplan, S. Akman, 1991, Molecular pharmacology.

5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial.

J. Doroshow, L. Leong, S. Akman, 1995, Cancer investigation.

Effects of storage on the binding of carboplatin to plasma proteins

J. Doroshow, M. Egorin, K. Erkmen, 2004, Cancer Chemotherapy and Pharmacology.

Abstract CN05-01: PARP inhibitors: Trapping of PARP and rational for combinations.

Y. Pommier, Joel Morris, J. Doroshow, 2013 .

Role of oxygen radical metabolism in the toxicity of anticancer quinones for rat heart myocytes in vitro

J. Doroshow, S. Akman, T. Burke, 1990 .

Modernizing Clinical Trials for Patients With Cancer.

N. Sharpless, J. Doroshow, 2019, JAMA.

Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer.

Y. Yen, J. Doroshow, L. Leong, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Expanded access trial of tocilizumab in COVID19+hospitalized cancer patients

W. McCaskill-Stevens, B. Freidlin, J. Doroshow, 2020 .

Cellular but not plasma pharmacokinetics of lometrexol correlate with the occurrence of cumulative hematological toxicity.

S. Groshen, J. Doroshow, F. Muggia, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis

J. Doroshow, L. Leong, S. Akman, 2000, Cancer Chemotherapy and Pharmacology.

Chemotherapy for murine ovarian cancer: a rationale for ip therapy with adriamycin.

R. Fisher, J. Doroshow, R. Ozols, 1979, Cancer treatment reports.

Abstract #5456: Correlation between inhibition of the activity of poly(ADP-ribose) polymerase (PARP) in human peripheral blood mononuclear cells (PBMCs) and tumor biopsies following treatment with ABT-888, an inhibitor of PARP

L. Rubinstein, J. Doroshow, A. Chen, 2009 .

Safety and feasibility of targeted agent combinations in solid tumours

James H. Doroshow, Myrtle Davis, J. Doroshow, 2013, Nature Reviews Clinical Oncology.

Antibody-independent capture of circulating tumor cells of non-epithelial origin with the ApoStream® system

Priya Balasubramanian, Anoop Menachery, James H Doroshow, 2017, PloS one.

A cross-study analysis of drug response prediction in cancer cell lines

Rick L. Stevens, Yvonne A. Evrard, Austin R. Clyde, 2021, Briefings Bioinform..

AACR-FDA-NCI Cancer Biomarkers Collaborative Consensus Report: Advancing the Use of Biomarkers in Cancer Drug Development

James H. Doroshow, J. Doroshow, W. Hait, 2010, Clinical Cancer Research.

Doxorubicin resistance conferred by selective enhancement of intracellular glutathione peroxidase or superoxide dismutase content in human MCF-7 breast cancer cells.

J. Doroshow, S. Akman, T. Burke, 1991, Free radical research communications.

Synergistic cytotoxicity between menadione and dicumarol vs. murine leukemia L1210.

R. Chlebowski, J. Doroshow, S. Akman, 1987, The Journal of pharmacology and experimental therapeutics.

Role of Se-dependent glutathione peroxidases in gastrointestinal inflammation and cancer.

J. Doroshow, F. Chu, R. Esworthy, 2004, Free radical biology & medicine.

Phase II trial of cisplatin and alpha-interferon in advanced malignant melanoma.

J. Doroshow, L. Leong, S. Akman, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Translational research in oncology—10 years of progress and future prospects

James H. Doroshow, J. Doroshow, S. Kummar, 2014, Nature Reviews Clinical Oncology.

Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study

J. Doroshow, D. Gandara, H. Lenz, 2012, Investigational New Drugs.

Analysis of Food and Drug Administration–Approved Anticancer Agents in the NCI60 Panel of Human Tumor Cell Lines

James H Doroshow, J. Doroshow, S. Holbeck, 2010, Molecular Cancer Therapeutics.

NADPH oxidases and cancer.

Han Liu, J. Doroshow, Smitha Antony, 2015, Clinical science.

NADPH oxidases: a perspective on reactive oxygen species production in tumor biology.

Han Liu, J. Doroshow, Smitha Antony, 2014, Antioxidants & redox signaling.

A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.

J. Doroshow, J. Wong, A. Wu, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Radiation-induced changes in established tumor immunity.

J. Doroshow, J. Vaage, T. Dubois, 1974, Cancer research.

Simple and sensitive method for the quantitative analysis of lometrexol in plasma using high-performance liquid chromatography with electrochemical detection.

J. Doroshow, F. Muggia, T. Synold, 1996, Journal of chromatography. B, Biomedical applications.

Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine.

J. Doroshow, I. Ifrim, G. Locker, 1981, The Journal of clinical investigation.

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study.

J. Doroshow, M. Slovak, F. Appelbaum, 2001, Blood.

Hepatic metastasis in granulosa cell tumor of the ovary

J. Doroshow, H. Pak, K. Margolin, 1985, Cancer.

Effect of anthracycline antibiotics on oxygen radical formation in rat heart.

J. Doroshow, 1983, Cancer research.

Prevention of doxorubicin-induced killing of MCF-7 human breast cancer cells by oxygen radical scavengers and iron chelating agents.

J. Doroshow, J. H. Doroshow, J. Doroshow, 1986, Biochemical and biophysical research communications.

Exon array analyses across the NCI-60 reveal potential regulation of TOP1 by transcription pausing at guanosine quartets in the first intron.

William C Reinhold, John N Weinstein, Jean-Louis Mergny, 2010, Cancer research.

Oxidative DNA base damage in MCF-10A breast epithelial cells at clinically achievable concentrations of doxorubicin.

James H Doroshow, J. Doroshow, S. Gaur, 2007, Biochemical pharmacology.

Reductive activation of mitomycin C: a delicate balance.

J. Doroshow, 1992, Journal of the National Cancer Institute.

Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies

J. Niland, Y. Yen, J. Doroshow, 2003, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics of Diastereoisomers of (6l?,5)-Folinic Acid (Leucovorin) in Humans during Constant High-Dose Intravenous Infusion1

J. Doroshow, J. Straw, E. Newman, 2006 .

Phase II trial of 5-fluorouracil, high-dose leucovorin calcium, and dipyridamole in advanced prostate cancer

J. Doroshow, L. Leong, S. Akman, 2005, Journal of Cancer Research and Clinical Oncology.

Effective initial therapy of advanced breast cancer with fluorouracil and high-dose, continuous infusion calcium leucovorin.

J. Doroshow, L. Leong, S. Akman, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics and toxicity of continuous infusion (6S)-folinic acid and bolus 5-fluorouracil in patients with advanced cancer.

J. Doroshow, L. Leong, S. Akman, 1992, Cancer research.

A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine, administered with tetrahydrouridine

J. Doroshow, H. Lenz, A. El-Khoueiry, 2015, Cancer Chemotherapy and Pharmacology.

Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU)

James H. Doroshow, Merrill J. Egorin, J. Doroshow, 2008, Cancer Chemotherapy and Pharmacology.

Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin.

J. Doroshow, G. Locker, C. Myers, 1980, The Journal of clinical investigation.

Abeloff's Clinical Oncology

James H. Doroshow, James Olen Armitage, John E. Niederhuber, 2013 .

Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase.

J. Doroshow, K. Davies, 1986, The Journal of biological chemistry.

3-Deazaguanine: Report of a phase I trial and drug-related cardiac toxicity

J. Doroshow, L. Leong, S. Akman, 1990, Investigational New Drugs.

Intravenous 5-fluoro-2′-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors

S. Steinberg, L. Rubinstein, J. Nieva, 2020, Cancer Chemotherapy and Pharmacology.

Fetal hemoglobin gene activation in a phase II study of 5,6-dihydro-5-azacytidine for bronchogenic carcinoma.

J. Doroshow, L. Leong, B. Carr, 1987, Cancer research.

NCI-60 Whole Exome Sequencing and Pharmacological CellMiner Analyses

P. Meltzer, K. Kohn, W. Reinhold, 2014, PloS one.

Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells

J. Doroshow, R. Parchment, Tara Hiltke, 2018, PloS one.

Effective implementation of novel MET pharmacodynamic assays in translational studies.

J. Doroshow, R. Parchment, M. Hollingshead, 2017, Annals of translational medicine.

Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays

Yvonne A. Evrard, W. Linehan, J. Doroshow, 2016, Clinical Cancer Research.

Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment

Benjamin J. Raphael, Yvonne A. Evrard, Jeffrey H. Chuang, 2021, Nature Communications.

Advances in using PARP inhibitors to treat cancer

J. Doroshow, A. Chen, R. Parchment, 2012, BMC Medicine.

PARP Inhibitors in Reproductive System Cancers: Current Use and Developments

J. Doroshow, A. Chen, R. Meehan, 2017, Drugs.

Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer

S. Steinberg, A. Oza, J. Doroshow, 2015, Clinical Cancer Research.

Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis).

P. Meltzer, P. Choyke, J. Doroshow, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

Shridar Ganesan, Jos Jonkers, Piet Borst, 2013, Cancer discovery.

Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors.

S. Steinberg, Y. Pommier, S. Bates, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Converting tabular data into images for deep learning with convolutional neural networks

Rick L. Stevens, Yvonne A. Evrard, R. Stevens, 2021, Scientific Reports.

Wee1 kinase as a target for cancer therapy

J. Doroshow, S. Kummar, K. Do, 2013, Cell cycle.

AACR Cancer Progress Report 2016

William Pao, Thomas J. Smith, Thomas J Smith, 2016, Clinical Cancer Research.

Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations.

J. Berzofsky, J. Doroshow, R. Parchment, 2016, Seminars in oncology.

The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity.

Larry Rubinstein, James H Doroshow, L. Rubinstein, 2017, Cancer research.

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

Yvonne A. Evrard, Michael W. Lloyd, Jeffrey H. Chuang, 2021, Nature Genetics.

CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute

P. Meltzer, W. Reinhold, Y. Pommier, 2012, Oncogene.

Principles of Molecularly Targeted Therapy: Present and Future

J. Doroshow, S. Kummar, A. Murgo, 2008 .

Learning curves for drug response prediction in cancer cell lines pdf

Thomas S. Brettin, Maulik Shukla, Rick L. Stevens, 2020, BMC Bioinformatics.

Enhanced Co-Expression Extrapolation (COXEN) Gene Selection Method for Building Anti-Cancer Drug Response Prediction Models

Fangfang Xia, Rick L Stevens, Maulik Shukla, 2020, Genes.

Ensemble transfer learning for the prediction of anti-cancer drug response

Maulik Shukla, Rick L. Stevens, Yitan Zhu, 2020, Scientific Reports.

AI Meets Exascale Computing: Advancing Cancer Research With Large-Scale High Performance Computing

Fangfang Xia, Rick Stevens, Eric Stahlberg, 2019, Front. Oncol..

The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line Panel.

Dmitriy Sonkin, Yingdong Zhao, Jianwen Fang, 2018, Cancer research.

TPM, FPKM, or Normalized Counts? A Comparative Study of Quantification Measures for the Analysis of RNA-seq Data from the NCI Patient-Derived Models Repository

Yvonne A. Evrard, L. McShane, J. Doroshow, 2021, Journal of Translational Medicine.

Decoding NADPH oxidase 4 expression in human tumors

A. Shah, J. Doroshow, H. Makhlouf, 2017, Redox biology.

PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components

J. Doroshow, A. Chen, R. Parchment, 2022, OncoTargets and therapy.

OTT_A_278092 165..180

J. Doroshow, A. Chen, R. Parchment, 2022 .

Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial.

Lisa M McShane, Robin D Harrington, Chih-Jian Lih, 2017, The Journal of molecular diagnostics : JMD.

Bacteria-Induced Intestinal Cancer in Mice with Disrupted Gpx1 and Gpx2 Genes

Mark M Huycke, James H Doroshow, J. Doroshow, 2004, Cancer Research.

Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial

T. Zimmerman, Helen X. Chen, J. Doroshow, 2011, British journal of haematology.

The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment

L. Staudt, D. Lowy, J. Doroshow, 2021, Cell.

Inhibiting the Activity of NADPH Oxidase in Cancer.

J. Doroshow, Smitha Antony, Mariam M. Konaté, 2020, Antioxidants & redox signaling.

Phase I study of PS-341 (bortezomib) with 5-fluorouracil/leucovorin (5-FU/LV) in advanced solid tumors: A California Cancer Consortium study.

J. Doroshow, D. Gandara, P. Gumerlock, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trastuzumab plus docetaxel in HER‐2/neu‐positive prostate carcinoma

J. Doroshow, D. Gandara, P. Gumerlock, 2004, Cancer.

Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC)

E. Cerami, I. Wistuba, Catherine J. Wu, 2021, Clinical Cancer Research.

Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study

Y. Yen, J. Doroshow, D. Gandara, 2009, Cancer Chemotherapy and Pharmacology.

First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile

L. Rubinstein, J. Doroshow, A. Chen, 2018, Investigational New Drugs.

ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.

Y. Pommier, R. Guha, Joel Morris, 2014, Cancer research.

Concerted changes in transcriptional regulation of genes involved in DNA methylation, demethylation, and folate-mediated one-carbon metabolism pathways in the NCI-60 cancer cell line panel in response to cancer drug treatment

R. Simon, A. Monks, C. Hose, 2016, Clinical Epigenetics.

Systematic Establishment of Robustness and Standards in Patient-Derived Xenograft Experiments and Analysis

Anuj Srivastava, Peter N. Robinson, Jeffrey S. Morris, 2019, bioRxiv.

What Can Be Done to Improve Research Biopsy Quality in Oncology Clinical Trials?

E. Pisano, L. Rubinstein, E. Levy, 2018, Journal of oncology practice.

Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors

J. Doroshow, R. Parchment, M. Hollingshead, 2018, Molecular Cancer Therapeutics.

Nox1 causes ileocolitis in mice deficient in glutathione peroxidase-1 and -2.

J. Doroshow, F. Chu, B. Shen, 2013, Free radical biology & medicine.

Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer

L. Rubinstein, J. Doroshow, L. Doyle, 2015, Investigational New Drugs.

Hydrogen peroxide-producing NADPH oxidases and the promotion of migratory phenotypes in cancer.

J. Doroshow, Mariam M. Konaté, Jennifer L. Meitzler, 2019, Archives of biochemistry and biophysics.

Molecular Mechanism of Adaphostin-mediated G1 Arrest in Prostate Cancer (PC-3) Cells

E. Sausville, J. Doroshow, K. Roy, 2006, Journal of Biological Chemistry.

Pharmacodynamic biomarker-driven trial of MK-2206, an AKT inhibitor, with AZD6244 (selumetinib), a MEK inhibitor, in patients with advanced colorectal carcinoma (CRC).

L. Rubinstein, J. Doroshow, P. M. Williams, 2012 .

Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study.

V. Sondak, J. Doroshow, C. Taylor, 1995, Journal of the National Cancer Institute.

Phase I trial of the triplet M6620 (formerly VX970) + veliparib + cisplatin in patients with advanced solid tumors.

L. Rubinstein, E. Levy, J. Doroshow, 2018 .

High doses of prochlorperazine for cisplatin‐induced emesis: A prospective, random, dose–response study

J. Doroshow, B. Carr, D. Blayney, 1987, Cancer.

A comparison of the antiemetic efficacy of prochlorperazine and metoclopramide for the treatment of cisplatin-induced emesis: a prospective, randomized, double-blind study.

L. R. Hill, J. Doroshow, C. Presant, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS).

J. Foster, J. Doroshow, A. Chen, 2021 .

Methodologic guidelines for the design of high-dose chemotherapy regimens.

J. Doroshow, K. Margolin, J. Longmate, 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements

James H. Doroshow, Jerry Collins, Helen X. Chen, 2010, Nature Reviews Drug Discovery.

Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies.

G. Giaccone, J. Doroshow, A. Calvert, 2009, European Journal of Cancer.

NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma

James H. Doroshow, Amy LeBlanc, Yves Pommier, 2018, Clinical Cancer Research.

Inhibition of cytoplasmic EZH2 induces antitumor activity through stabilization of the DLC1 tumor suppressor protein

D. Lowy, J. Doroshow, K. Politi, 2021, Nature Communications.

Abstract B080: Update on the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH/EAY131) precision medicine trial

R. Gray, A. Iafrate, J. Sklar, 2018 .

A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study

David D. Smith, James H. Doroshow, Paul Frankel, 2008, Clinical Cancer Research.

Monitoring Drug-Induced γH2AX as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells

Yvonne A. Evrard, L. Rubinstein, J. Doroshow, 2010, Clinical Cancer Research.

Preclinical Modeling of a Phase 0 Clinical Trial: Qualification of a Pharmacodynamic Assay of Poly (ADP-Ribose) Polymerase in Tumor Biopsies of Mouse Xenografts

L. Rubinstein, J. Doroshow, R. Parchment, 2008, Clinical Cancer Research.

Preclinical Development of Molecularly Targeted Agents in Oncology

J. Doroshow, J. Tomaszewski, 2008 .

A phase II study of multikinase inhibitor sorafenib in patients with relapsed non-small cell lung cancer (NSCLC)

G. Giaccone, P. Choyke, J. Doroshow, 2008 .

A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas

Larry Rubinstein, James H Doroshow, L. Rubinstein, 2012, Clinical Cancer Research.

284 Differential Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

Y. Pommier, J. Doroshow, S. Takeda, 2012 .

Molecular mechanisms underlying chronic inflammation-associated cancers.

James H Doroshow, J. Doroshow, Smitha Antony, 2014, Cancer letters.

Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay

W. Reinhold, Y. Pommier, J. Doroshow, 2017, PloS one.

Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas

J. Doroshow, A. Chen, S. Kummar, 2013, Cancer Chemotherapy and Pharmacology.

The root causes of pharmacodynamic assay failure.

J. Doroshow, A. Chen, H. Makhlouf, 2016, Seminars in oncology.

Development and Use of Integral Assays in Clinical Trials

R. Schilsky, M. Leblanc, J. Doroshow, 2012, Clinical Cancer Research.

A Phase II Trial of Flavopiridol (NSC #649890) in Patients with Previously Untreated Metastatic Androgen-Independent Prostate Cancer

P. Kantoff, W. Oh, J. Doroshow, 2004, Clinical Cancer Research.

NADPH oxidase 1 is highly expressed in human large and small bowel cancers

Han Liu, J. Doroshow, R. Chuaqui, 2020, PloS one.

Expression of NADPH oxidase homologues and accessory genes in human cancer cell lines, tumours and adjacent normal tissues

J. Doroshow, K. Roy, A. Juhász, 2009, Free radical research.

A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer.

S. Steinberg, P. Choyke, M. Raffeld, 2015, Clinical colorectal cancer.

GeneMed: An Informatics Hub for the Coordination of Next-Generation Sequencing Studies that Support Precision Oncology Clinical Trials

Yingdong Zhao, Alida Palmisano, Ming-Chung Li, 2015, Cancer informatics.

Abstract LB-B18: Epithelial to mesenchymal transition in human tumor biopsies: Quantitative, histopathological proof of the existence of EMT in vivo by immunofluorescence microscopy

J. Doroshow, A. Chen, R. Chuaqui, 2015 .

Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors

S. Steinberg, P. Choyke, J. Doroshow, 2014, Cancer Chemotherapy and Pharmacology.

Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic Inhibition

James H. Doroshow, Yves Pommier, Shunichi Takeda, 2014, The Journal of Pharmacology and Experimental Therapeutics.

Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.

Larry Rubinstein, Jerry Collins, Seth M Steinberg, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition.

J. Doroshow, D. Gandara, H. Lenz, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Sequential Vinorelbine and Docetaxel in Advanced Non-small Cell Lung Cancer Patients Age 70 and Older and/or with a Performance Status of 2: A Phase II Trial of the Southwest Oncology Group (S0027)

J. Crowley, J. Doroshow, C. Moinpour, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.

Y. Pommier, L. Rubinstein, L. Jia, 2011, Cancer research.

Molecular targets in cancer therapy

J. Doroshow, S. Kummar, 2013, Expert review of anticancer therapy.

Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development.

J. Doroshow, R. Parchment, 2016, Seminars in oncology.

Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas

J. Foster, L. Rubinstein, J. Doroshow, 2021, Clinical Cancer Research.

United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies.

J. Doroshow, S. Kummar, W. Jeong, 2013, Current problems in cancer.

Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer

Y. Yen, J. Doroshow, D. Gandara, 2004, Cancer Chemotherapy and Pharmacology.

Genomics and the History of Precision Oncology.

J. Doroshow, D. Doroshow, 2020, Surgical oncology clinics of North America.

From the Broad Phase II Trial to Precision Oncology: A Perspective on the Origins of Basket and Umbrella Clinical Trial Designs in Cancer Drug Development

J. Doroshow, D. Doroshow, 2019, Cancer journal.

Loss of 53 BP 1 causes PARP inhibitor resistance in BRCA 1-mutated mouse mammary tumors

Shridar Ganesan, James H. Doroshow, S. Ganesan, 2012 .

Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial.

J. Doroshow, V. Israel, D. Gandara, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors

L. Rubinstein, J. Doroshow, A. Chen, 2021, Clinical Cancer Research.

Phase 1 study of Z-endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumors

P. Choyke, L. Rubinstein, J. Doroshow, 2021, Oncotarget.

Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial

David J. Sims, J. Foster, R. Simon, 2021, JCO precision oncology.

A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction

L. Rubinstein, J. Doroshow, A. Chen, 2019, British journal of clinical pharmacology.

Isoform- and Phosphorylation-specific Multiplexed Quantitative Pharmacodynamics of Drugs Targeting PI3K and MAPK Signaling in Xenograft Models and Clinical Biopsies

D. Esposito, J. Doroshow, A. Chen, 2021, Molecular Cancer Therapeutics.

Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies.

D. Findley, J. Doroshow, R. Krance, 1987, Blood.

Comparative Oncology Assessment of a Novel Inhibitor of Valosin-Containing Protein in Tumor-Bearing Dogs

J. Doroshow, B. Mroczkowski, T. Chou, 2022, Molecular Cancer Therapeutics.

Plasmid-Based Materials as Multiplex Quality Controls and Calibrators for Clinical Next-Generation Sequencing Assays.

Robin D Harrington, Chih-Jian Lih, Courtney H Bouk, 2016, The Journal of molecular diagnostics : JMD.

Pharmacokinetics of high‐dose etoposide

J. Doroshow, S. Forman, Edward M Newman, 1988, Clinical pharmacology and therapeutics.

Modulation of selenium-dependent glutathione peroxidase activity enhances doxorubicin-induced apoptosis, tumour cell killing and hydroxyl radical production in human NCI/ADR-RES cancer cells despite high-level P-glycoprotein expression

J. Doroshow, A. Juhász, 2019, Free radical research.

Effect of CD34 " Selection and Various Schedules of Stem Cell Reinfusion and Granulocyte Colony-Stimulating Factor Priming on Hematopoietic Recovery After High-Dose Chemotherapy for Breast Cancer

J. Doroshow, L. Leong, T. Odom-Maryon, 1997 .

Effect of CD34+ selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancer.

J. Doroshow, L. Leong, T. Odom-Maryon, 1997, Blood.

Pharmacodynamics of first-in-class p97 inhibitors that disrupt protein homeostasis in cancer.

J. Doroshow, R. Parchment, T. Chou, 2018 .

A phase II trial of CI-921 in advanced malignancies

N. Robert, J. Doroshow, L. Panasci, 1992, Investigational New Drugs.

A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.

Paul J Yazaki, Anna M Wu, James H Doroshow, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

A Phase I Trial of 90 Y-Anti-Carcinoembryonic Antigen Chimeric T84.66 Radioimmunotherapy with 5-Fluorouracil in Patients with Metastatic Colorectal Cancer

J. Doroshow, J. Wong, A. Wu, 2003 .

TET2 and DNMT3A mutations and exceptional response to 4′-thio-2′-deoxycytidine in human solid tumor models

Dat Quoc Nguyen, J. Doroshow, Sherry X. Yang, 2021, Journal of Hematology & Oncology.

Pharmacokinetics of Cetuximab After Administration of Escalating Single Dosing and Weekly Fixed Dosing in Patients with Solid Tumors

M. Hidalgo, J. Doroshow, A. Tan, 2006, Clinical Cancer Research.

Antiproliferative mechanisms of action of the flavin dehydrogenase inhibitors diphenylene iodonium and di-2-thienyliodonium based on molecular profiling of the NCI-60 human tumor cell panel.

J. Doroshow, S. Holbeck, Smitha Antony, 2012, Biochemical pharmacology.

BRCA Mutation and PARP Inhibitors

J. Doroshow, A. Chen, S. Kummar, 2013, Handbook of Therapeutic Biomarkers in Cancer.

Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer

S. Steinberg, A. Oza, J. Doroshow, 2016, Investigational New Drugs.

On the Design of Combination Cancer Therapy

James H. Doroshow, J. Doroshow, R. Simon, 2017, Cell.

Poly(ADP-ribose) polymerase and XPF–ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells

Y. Pommier, J. Doroshow, K. Agama, 2011, Nucleic acids research.

DNA base modifications induced in isolated human chromatin by NADH dehydrogenase-catalyzed reduction of doxorubicin.

J. Doroshow, S. Akman, M. Dizdaroglu, 1992, Biochemistry.

Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent

Larry Rubinstein, Yves Pommier, Diana Nguyen, 2011, Cell cycle.

Cediranib for metastatic alveolar soft part sarcoma.

S. Steinberg, R. Simon, P. Choyke, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized trial of oral cyclophosphamide (C) with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma.

S. Steinberg, A. Oza, J. Doroshow, 2012 .

A phase I combination study of olaparib (AZD2281; KU-0059436) and cisplatin (C) plus gemcitabine (G) in adults with solid tumors.

G. Giaccone, J. Doroshow, R. Parchment, 2010 .

Pharmacodynamic response in phase I combination study of ABT-888 and topotecan in adults with refractory solid tumors and lymphomas.

L. Rubinstein, J. Doroshow, A. Chen, 2010 .

Bortezomib Plus Docetaxel in Advanced Non-small Cell Lung Cancer and Other Solid Tumors: A Phase I California Cancer Consortium Trial

J. Doroshow, D. Gandara, H. Lenz, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Cancer Biology and Signal Transduction Stereospeci fi c PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

Y. Pommier, Joel Morris, J. Doroshow, 2014 .

Drug development in oncology: classical cytotoxics and molecularly targeted agents.

J. Doroshow, S. Kummar, A. Murgo, 2006, British journal of clinical pharmacology.

Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.

J. Doroshow, C. Takimoto, J. Grem, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials

C. Flowers, L. Rubinstein, J. Doroshow, 2022, The Lancet.

Quadruplex DNA formation in a region of the tRNA gene supF associated with hydrogen peroxide mediated mutations.

S. S. Smith, J. Doroshow, S. Akman, 1991, Biochemistry.

Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations

J. Stenvang, N. Brünner, Y. Pommier, 2016, Journal of Experimental & Clinical Cancer Research.

Phase 0 Clinical Trials: Conceptions and Misconceptions

Larry Rubinstein, Jerry Collins, James H Doroshow, 2008, Cancer journal.

Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study.

R. Fisher, M. Atkins, J. Sosman, 1997, The cancer journal from Scientific American.

Establishing proof of mechanism: Assessing target modulation in early-phase clinical trials.

L. Rubinstein, J. Doroshow, S. Kummar, 2016, Seminars in oncology.

Role of Reactive-Oxygen Metabolism in Cardiac Toxicity of Anthracycline Antibiotics

J. Doroshow, 1994 .

Characterization of the aqueous decomposition products of (+)1,2-bis(3,5-dioxopiperazinyl-1-yl)-propane (ICRF-187) by liquid chromatographic and mass spectral analysis.

J. Doroshow, T. Lee, T. Burke, 1991, Journal of pharmaceutical sciences.

Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study.

J. Doroshow, D. Gandara, H. Lenz, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Clinical Evolution of Epithelial-Mesenchymal Transition in Human Carcinomas.

L. Rubinstein, J. Doroshow, A. Chen, 2019, Cancer research.

Identification of pharmacodynamic biomarkers and common molecular mechanisms of response to genotoxic agents in cancer cell lines

R. Simon, A. Monks, C. Hose, 2019, Cancer Chemotherapy and Pharmacology.

Theory and practice of clinical pharmacodynamics in oncology drug development.

J. Doroshow, R. Parchment, 2016, Seminars in oncology.

Patterns of Enrollment in Cancer Treatment Trials During the COVID-19 Pandemic at National Cancer Institute–Designated Cancer Centers

J. Doroshow, H. Ciolino, S. Prindiville, 2022, Cancer journal.

Compressing drug development timelines in oncology using phase '0' trials

S. Steinberg, L. Rubinstein, O. Pickeral, 2007, Nature Reviews Cancer.

A Randomized Phase II Trial of the Matrix Metalloproteinase Inhibitor BMS-275291 in Hormone-Refractory Prostate Cancer Patients with Bone Metastases

J. Doroshow, D. Gandara, H. Lenz, 2006, Clinical Cancer Research.

Phase II Study of Continuous Subcutaneous Interferon-Alfa Combined with Cisplatin in Advanced Malignant Melanoma

A. Harris, S. Fosså, A. Einstein, 1992 .

Experimental animal models of adriamycin cardiotoxicity.

J. Doroshow, G. Locker, C. Myers, 1979, Cancer treatment reports.

A Phase I Study of Ganetespib and Ziv‐Aflibercept in Patients with Advanced Carcinomas and Sarcomas

L. Rubinstein, J. Doroshow, A. Chen, 2018, The oncologist.

A Phase II Clinical Trial of Interleukin‐2 and Lymphokine‐Activated Killer Cells in Advanced Colorectal Carcinoma

R. Fisher, M. Atkins, J. Doroshow, 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Dolastatin-10 in Metastatic Melanoma: A Phase II and Pharmokinetic Trial of the California Cancer Consortium

J. Doroshow, D. Gandara, R. Gonzalez, 2004, Investigational New Drugs.

Human tumor derived cell lines express phospholipid hydroperoxide glutathione peroxidase (PHGPX)

J. Doroshow, F. Ursini, F. Chu, 1990 .

Abrogation of the selectivity of adriamycin for negatively-charged phospholipids by 14-valerate side chain substitution.

J. Doroshow, R. Seshadri, T. Burke, 1990, Cancer biochemistry biophysics.

Identification of novel PARP inhibitors using a cell-based TDP1 inhibitory assay in a quantitative high-throughput screening platform.

Y. Pommier, Ruili Huang, A. Jadhav, 2014, DNA repair.

Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies

Y. Yen, J. Doroshow, L. Leong, 2004, Cancer Chemotherapy and Pharmacology.

Esorubicin in refractory metastatic carcinoma of the breast: a Northern California Oncology Group Study.

R. Carlson, J. Doroshow, F. Torti, 1987, Cancer treatment reports.

Renal, volume, and hormonal changes during therapeutic administration of recombinant interleukin-2 in man.

J. Doroshow, S. Textor, D. Blayney, 1987, The American journal of medicine.

Phase II trial of esorubicin in advanced pancreatic adenocarcinoma.

J. Doroshow, B. Carr, D. Blayney, 1986, Cancer treatment reports.

Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy

J. Doroshow, L. Leong, S. Akman, 2005, Investigational New Drugs.

Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma.

R. Fisher, J. Doroshow, G. Weiss, 1989, Journal of the National Cancer Institute.

Abeloff's Clinical Oncology (5th ed.)

J. Armitage, J. Doroshow, J. Tepper, 2014 .

Fluorescence lifetimes of anthracycline drugs in phospholipid bilayers determined by frequency-domain fluorometry

James H. Doroshow, Thomas G. Burke, Henryk M. Malak, 1990, Photonics West - Lasers and Applications in Science and Engineering.

The clinical features of hepatic angiosarcoma

J. Doroshow, L. Zwelling, B. Chabner, 1979 .

A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinoma.

M. Atkins, J. Sosman, J. Doroshow, 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma.

R. Fisher, M. Atkins, J. Doroshow, 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Phase I study of bryostatin-1 in combination with cisplatin in treating patients with metastatic or unresectable solid tumors including non small-cell lung cancer.

J. Doroshow, D. Gandara, H. Lenz, 1999, Clinical lung cancer.

Trimetrexate in locally advanced or metastatic adenocarcinoma of the pancreas

R. Carlson, K. Lamborn, J. Doroshow, 1990, Investigational New Drugs.

Pharmacokinetics of leucovorin (D,L-5-formyltetrahydrofolate) after intravenous injection and constant intravenous infusion.

J. Doroshow, J. Straw, E. Newman, 1987, NCI monographs : a publication of the National Cancer Institute.

Mutation of potassium permanganate- and hydrogen peroxide-treated plasmid pZ189 replicating in CV-1 monkey kidney cells.

J. Doroshow, S. Akman, M. Dizdaroglu, 1991, Mutation research.

Exposure time versus cytotoxicity for anticancer agents

David M. Evans, L. Rubinstein, J. Doroshow, 2019, Cancer Chemotherapy and Pharmacology.

A phase 1 trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients with solid tumors and lymphomas.

L. Rubinstein, J. Doroshow, A. Chen, 2016 .

Oxidative DNA base modifications in peripheral blood mononuclear cells of patients treated with high-dose infusional doxorubicin.

J. Doroshow, E. Gajewski, S. Akman, 2001, Blood.

The Gdac1 locus modifies spontaneous and Salmonella-induced colitis in mice deficient in either Gpx2 or Gpx1 gene.

J. Doroshow, F. Chu, T. Leto, 2013, Free radical biology & medicine.

A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas

E. Sausville, J. Dancey, J. Doroshow, 2009, Cancer Chemotherapy and Pharmacology.

Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors

Yun Yen, James H. Doroshow, Adam Mamelak, 2010, Cancer Chemotherapy and Pharmacology.

Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy.

S. Vuk-Pavlović, Y. Yen, J. Doroshow, 1999, Blood.

Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer

J. Doroshow, L. Leong, P. Frankel, 2002, British Journal of Cancer.

Dexamethasone and Tofacitinib suppress NADPH oxidase expression and alleviate very-early-onset ileocolitis in mice deficient in GSH peroxidase 1 and 2.

J. Doroshow, F. Chu, B. Shen, 2019, Life sciences.

A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma.

J. Doroshow, J. Bennett, H. Muss, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Exogenous DNA enhances DUOX2 expression and function in human pancreatic cancer cells by activating the cGAS-STING signaling pathway.

J. Doroshow, Smitha Antony, K. Roy, 2023, Free radical biology & medicine.

An audit strategy for time-to-event outcomes measured with error: Application to five randomized controlled trials in oncology

R. Gray, B. Freidlin, E. Korn, 2013, Clinical trials.

Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: Comparison of real‐time reverse transcription‐PCR vs. Relative quantification reverse transcription‐PCR utilizing DNA sequencer analysis of PCR products

Y. Yen, J. Doroshow, D. Gandara, 2003, Journal of clinical laboratory analysis.

Deficiency in Duox2 activity alleviates ileitis in GPx1- and GPx2-knockout mice without affecting apoptosis incidence in the crypt epithelium

J. Doroshow, F. Chu, T. Leto, 2016, Redox biology.

NADPH oxidase-1 deficiency offers little protection in Salmonella typhimurium-induced typhlitis in mice

J. Doroshow, F. Chu, B. Shen, 2016, World journal of gastroenterology.

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers

James H. Doroshow, Yves Pommier, Robert J. Kinders, 2010, Clinical Cancer Research.

Phase l study assessing a two-consecutive-day (QD x 2) dosing schedule of the HSP90 inhibitor, AT13387, in patients with advanced solid tumors.

J. Doroshow, A. Chen, J. Trepel, 2012 .

Up-regulation and Sustained Activation of Stat1 Are Essential for Interferon-γ (IFN-γ)-induced Dual Oxidase 2 (Duox2) and Dual Oxidase A2 (DuoxA2) Expression in Human Pancreatic Cancer Cell Lines*

J. Doroshow, Smitha Antony, K. Roy, 2011, The Journal of Biological Chemistry.

The role of the National Cancer Institute in drug development.

J. Doroshow, 2005, Clinical advances in hematology & oncology : H&O.

Rationale for PARP inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition

Y. Pommier, Joel Morris, J. Doroshow, 2014 .

Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1α in Advanced Solid Tumors

S. Steinberg, P. Choyke, M. Raffeld, 2011, Clinical Cancer Research.

Nox4 regulates InsP3 receptor‐dependent Ca2+ release into mitochondria to promote cell survival

A. Shah, J. Doroshow, R. Fleck, 2020, The EMBO journal.

Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycyticine (FdCyd) & its metabolites 5-fluoro-2'-deoxyuridine (FdUrd), 5-fluorouracil (FU), 5-fluorouridine (FUrd), & 5-fluorocytosine (FC) in plasma of patients treated with FdCyd.

J. Doroshow, H. Lenz, M. Egorin, 2006, Journal of Clinical Oncology.

Phase I trial of the oral histone deacetylase inhibitor MS-275 administered with food.

J. Doroshow, G. Melillo, J. Trepel, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-in-Human Phase 0 Trial of Oral 5-Iodo-2-Pyrimidinone-2′-Deoxyribose in Patients with Advanced Malignancies

Larry Rubinstein, Pamela Harris, James H Doroshow, 2013, Clinical Cancer Research.

IL-4 and IL-17A Cooperatively Promote Hydrogen Peroxide Production, Oxidative DNA Damage, and Upregulation of Dual Oxidase 2 in Human Colon and Pancreatic Cancer Cells

Han Liu, J. Doroshow, R. Chuaqui, 2019, The Journal of Immunology.

DNA damage, demethylation and anticancer activity of DNA methyltransferase (DNMT) inhibitors

J. Doroshow, Sherry X. Yang, M. Hollingshead, 2023, Scientific Reports.

Validation of a hypoxia-inducible factor-1 alpha specimen collection procedure and quantitative enzyme-linked immunosorbent assay in solid tumor tissues.

J. Doroshow, R. Parchment, S. Kummar, 2014, Analytical Biochemistry.

Cancer Therapy : Clinical Multihistology , Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1 a in Advanced Solid Tumors

S. Steinberg, P. Choyke, M. Raffeld, 2011 .

A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A

Y. Yen, J. Doroshow, L. Leong, 2000, Cancer Chemotherapy and Pharmacology.

Anthracycline dose intensity: clinical pharmacology and pharmacokinetics of high-dose doxorubicin administered as a 96-hour continuous intravenous infusion.

J. Doroshow, T. Synold, 1996, The Journal of infusional chemotherapy.

Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.

S. Steinberg, L. Rubinstein, O. Pickeral, 2007, Molecular interventions.

Predicting tumor cell line response to drug pairs with deep learning

Fangfang Xia, Thomas S. Brettin, Sergei Maslov, 2018, BMC Bioinformatics.

Predicting tumor cell line response to drug pairs with deep learning

Rick L. Stevens, Yvonne A. Evrard, Jonathan E. Allen, 2018, BMC Bioinformatics.

Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas.

J. Doroshow, K. Kurdziel, G. Kaur, 2013, Nuclear medicine and biology.

National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.

Lisa McShane, Mickey Williams, L. Staudt, 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Selecting systemic cancer therapy one patient at a time: is there a role for molecular profiling of individual patients with advanced solid tumors?

James H Doroshow, J. Doroshow, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 0 Trials: Expediting the Development of Chemoprevention Agents

J. Doroshow, S. Kummar, 2011, Cancer Prevention Research.

Role of Phase 0 trials in drug development.

J. Doroshow, S. Kummar, 2009, Future medicinal chemistry.

Oncologic Phase 0 Trials Incorporating Clinical Pharmacodynamics: from Concept to Patient

J. Doroshow, R. Parchment, 2008, Clinical Cancer Research.

Designing Phase 0 Cancer Clinical Trials

S. Steinberg, L. Rubinstein, J. Doroshow, 2008, Clinical Cancer Research.

Fluorouracil and leucovorin in advanced breast cancer.

J. Doroshow, L. Leong, S. Akman, 1993, Advances in experimental medicine and biology.

Phase I trial of fenretinide lym-x-sorb oral powder in adults with solid tumors and lymphomas.

J. Doroshow, S. Kummar, A. Murgo, 2011, Anticancer research.

Phase II trial of 5-fluorouracil and high-dose folinic acid as first- or second-line therapy for advanced breast cancer.

S. Green, J. Doroshow, L. Leong, 1994, American journal of clinical oncology.

A pilot trial of oral topotecan (TPT) in patients with refractory advanced solid neoplasms expressing HIF-1{alpha}.

P. Choyke, M. Raffeld, J. Doroshow, 2010 .

Phase II trial of piroxantrone in advanced non-small cell carcinoma of the lung

J. Crowley, J. Doroshow, R. Livingston, 1992, Investigational New Drugs.

Adenocarcinoma of the small bowel: changes in the landscape?

J. Doroshow, S. Kummar, G. Speranza, 2010, Current opinion in oncology.

Control of doxorubicin-induced, reactive oxygen-related apoptosis by glutathione peroxidase 1 in cardiac fibroblasts

J. Doroshow, R. Esworthy, F. Chu, 2019, Biochemistry and biophysics reports.

Utility of 18F-fluoroestradiol (18F-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy

P. Choyke, J. Doroshow, A. Chen, 2017, European Journal of Nuclear Medicine and Molecular Imaging.

ROADMAPS: An Online Database of Response Data, Dosing Regimens, and Toxicities of Approved Oncology Drugs as Single Agents to Guide Preclinical In Vivo Studies

J. Doroshow, M. Hollingshead, J. Collins, 2022, Cancer research.

Activation of TLR4 Is Required for the Synergistic Induction of Dual Oxidase 2 and Dual Oxidase A2 by IFN-γ and Lipopolysaccharide in Human Pancreatic Cancer Cell Lines

Han Liu, J. Doroshow, M. Hollingshead, 2013, The Journal of Immunology.

Effects of Iodonium Analogs on Nadph Oxidase 1 in Human Colon Cancer Cells

J. Doroshow, K. Roy, Jiamo Lu, 2021, Antioxidants.

Inhibition of poly (ADP-ribose) polymerase (PARP) by ABT-888 in patients with advanced malignancies: Results of a phase 0 trial

L. Rubinstein, J. Doroshow, R. Parchment, 2007 .

PANEL 2 Improved Insights into Effects of Cancer Therapies

D. Berry, J. Doroshow, R. DuBois, 2008 .

TPWshiny: an interactive R/Shiny app to explore cell line transcriptional responses to anti-cancer drugs

Yingdong Zhao, James H. Doroshow, Alida Palmisano, 2021, Bioinform..

Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma

S. Steinberg, J. Doroshow, A. Chen, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Antiangiogenic approaches for the treatment of advanced synovial sarcomas

J. Doroshow, S. Kummar, K. Do, 2012, Current opinion in oncology.

National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

B. Freidlin, J. Berlin, K. Flaherty, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

State of the Art: Toward Improving Outcomes of Lung and Liver Tumor Biopsies in Clinical Trials-A Multidisciplinary Approach.

P. Schirmacher, W. Travis, M. Kuo, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An evaluation of cediranib as a new agent for alveolar soft part sarcoma (ASPS).

S. Steinberg, P. Choyke, A. Monks, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacodynamic end points in early phase oncology trials

J. Doroshow, S. Kummar, G. Speranza, 2012 .

Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy.

Y. Yen, J. Doroshow, L. Leong, 2004, Journal of Clinical Oncology.

Phase I study of 5-day continuous infusion fluorodeoxyuridine and high-dose folinic acid with oral hydroxyurea

J. Doroshow, L. Leong, S. Akman, 2004, Cancer Chemotherapy and Pharmacology.

Phase I study of the PARP inhibitor olaparib (O) in combination with carboplatin (C) in BRCA1/2 mutation carriers with breast (Br) or ovarian (Ov) cancer (Ca).

E. Kohn, L. Minasian, J. Doroshow, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract 4527: Pharmacodynamic and pathway analysis of three presumed inhibitors of poly (ADP-ribose) polymerase: ABT-888, AZD2281, and BSI201

J. Doroshow, M. Kadota, R. Parchment, 2011 .

Redox phospholipidomics discovers pro-ferroptotic death signals in A375 melanoma cells in vitro and in vivo

H. Bayır, J. Doroshow, R. Parchment, 2023, Redox biology.

The statistics of phase 0 trials

S. Steinberg, L. Rubinstein, J. Doroshow, 2010, Statistics in medicine.

Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas

S. Steinberg, L. Rubinstein, J. Doroshow, 2009, Cancer biology & therapy.

Phase 0 Trials in Oncology

J. Doroshow, S. Kummar, 2014 .

one γ H 2 AX and Poly ( ADP-Ribose ) as Clinical rmacodynamic Biomarkers

Y. Pommier, J. Doroshow, R. Parchment, 2010 .

Poly-adeninosinediphosphate-ribose polymerase inhibitors as sensitizers for therapeutic treatments in human tumor and blood mononuclear cells

Y. Pommier, J. Doroshow, R. Parchment, 2007 .

A prospective randomized trial of alpha 2B-interferon/gamma-interferon or the combination in advanced metastatic renal cell carcinoma.

J. Doroshow, K. Foon, P. Narayan, 1988, Journal of biological response modifiers.

Phase III Clinical Trial Development: A Process of Chutes and Ladders

James H. Doroshow, David M. Dilts, Steven K. Cheng, 2010, Clinical Cancer Research.

tes and Ladders

J. Doroshow, A. Sandler, S. Cheng, 2010 .

Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma.

R. Fisher, M. Atkins, J. Doroshow, 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy.

Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations

J. Stenvang, N. Brünner, Y. Pommier, 2016, Journal of experimental & clinical cancer research : CR.

Notch1 phenotype and clinical stage progression in non-small cell lung cancer

L. Rubinstein, J. Doroshow, Sherry X. Yang, 2015, Journal of Hematology & Oncology.

Development of a quantitative enzyme immunoassay for measurement of PAR as a pharmacodynamic biomarker of PARP activity

L. Rubinstein, J. Doroshow, X. Liu, 2006 .

Role of adaptive randomization in developing novel therapies for patients with breast cancer

J. Doroshow, A. Chen, R. Meehan, 2016 .

TPM, FPKM, or Normalized Counts? A Comparative Study of Quantification Measures for the Analysis of RNA-seq Data from the NCI Patient-Derived Models Repository

Yvonne A. Evrard, L. McShane, J. Doroshow, 2021, Journal of Translational Medicine.

The NCI-MATCH trial: lessons for precision oncology

Carlos L. Arteaga, David J. Sims, R. Gray, 2023, Nature Medicine.

Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer.

J. Doroshow, D. Gandara, H. Lenz, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Structures Supporting Cancer Clinical Trials

M. Christian, J. Doroshow, M. Mooney, 2020, Abeloff's Clinical Oncology.

Safety and tolerability of veliparib, an oral PARP inhibitor, and M6620 (VX-970), an ATR inhibitor, in combination with cisplatin in patients with refractory solid tumors.

L. Rubinstein, J. Doroshow, A. Chen, 2019, Journal of Clinical Oncology.

Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).

L. Rubinstein, J. Doroshow, A. Chen, 2020 .

Pharmacologic Basis for High‐Dose Chemotherapy

J. Doroshow, T. Synold, 2007 .

Evidence of in vivo efficacy for the indenoisoquinolines linked with pharmacodynamic markers for γH2AX

Y. Pommier, J. Doroshow, R. Parchment, 2007 .

Abstract A106: Investigation of 5-fluorodeoxycytidine with tetrahydrouracil as a demethylation regimen in solid tumors.

J. Doroshow, R. Parchment, S. Kummar, 2011 .

Overcoming resistance to targeted anticancer drugs.

J. Doroshow, 2013, The New England journal of medicine.

Angiogenesis inhibition in metastatic hormone refractory prostate cancer (HRPC): A randomized phase II trial of two doses of the matrix metalloproteinase inhibitor (MMPI) BMS-275291.

J. Doroshow, D. Gandara, E. Vokes, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multiplex immunofluorescence assay to assess immune checkpoint inhibitor-targeted CD8 activation and tumor colocalization in FFPE tissues.

J. Doroshow, A. Chen, R. Parchment, 2019, Journal of Clinical Oncology.

CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute

P. Meltzer, W. Reinhold, Y. Pommier, 2012, Oncogene.

Abeloff's Clinical Oncology: Fifth Edition

J. Armitage, J. Doroshow, J. Tepper, 2013 .

A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas

S. Steinberg, J. Doroshow, J. Trepel, 2013, Cancer Chemotherapy and Pharmacology.

268 CellMiner: a Web-Based Suite of Genomic and Pharmacologic Tools to Explore Transcript and Drug Patterns in the NCI-60 Cell Line Set

K. Kohn, W. Reinhold, Y. Pommier, 2012 .

Cancer Cell Lines Lipopolysaccharide in Human Pancreatic and γ Dual Oxidase A 2 by IFN-Synergistic Induction of Dual Oxidase 2 and Activation of TLR 4 Is Required for the Roy and

Han Liu, J. Doroshow, M. Hollingshead, 2013 .

A phase I study of ABT-888 (A) in combination with metronomic cyclophosphamide (C) in adults with refractory solid tumors and lymphomas.

J. Doroshow, A. Chen, D. Gandara, 2010 .

Novel clinical indenoisoquinoline topoisomerase I inhibitors: a twist around the camptothecins

Y. Pommier, J. Doroshow, M. Cushman, 2018, OncoTarget.

A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine.

R. Bonow, J. Doroshow, G. Locker, 1983, Seminars in oncology.

PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery

Yvonne A. Evrard, David M. Rocke, Jessica J. Andrews, 2022, NAR cancer.

PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery

Steven B. Neuhauser, Yvonne A. Evrard, Michael W. Lloyd, 2021, bioRxiv.

Abstract LB-B20: Characterization and Enumeration of Multiple Circulating Tumor Cell Phenotypes Using Two Distinct Platforms Establishes Presence of Epithelial-Mesenchymal Transition CTCs in Patients

J. Doroshow, A. Chen, R. Parchment, 2015 .

Clinical Cancer esearch cer Therapy : Preclinical elopment of a Validated Immunofluorescence Assay γ H 2 AX as a Pharmacodynamic Marker of R oisomerase I Inhibitor Activity

Yvonne A. Evrard, Y. Pommier, L. Rubinstein, 2010 .

Development and validation of a quantitative assay for γH2AX in needle biopsies using topoisomerase I inhibitors

J. Doroshow, R. Parchment, J. Ji, 2007 .

140 Phase I radioimmunotherapy trial evaluating 90Yttrium labeled anti-cea chimeric T84.66 in patients with metastatic cea-producing malignancies

James H. Doroshow, Anna M. Wu, Tamara Odom-Maryon, 1997 .

The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult With Pediatric Cancer

Allison P. Heath, A. Kerlavage, L. Staudt, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Feasibility of molecular profiling based assignment of cancer treatment (MPACT): A randomized NCI precision medicine study.

David J. Sims, R. Simon, L. Rubinstein, 2016 .

Phase II trial of etoposide, vincristine, and high-dose cisplatin in advanced non-small cell lung cancer.

J. Doroshow, C. Presant, B. Carr, 1985, Cancer treatment reports.

CCI-779 in metastatic melanoma: A phase II trial of the California Cancer Consortium

J. Doroshow, J. Weber, T. Gajewski, 2004 .

Daunorubicin-stimulated reactive oxygen metabolism in cardiac sarcosomes.

J. Doroshow, J H Doroshow, J. Reeves, 1981, Biochemical pharmacology.

Modulation of glutathione peroxidase expression by selenium: effect on human MCF-7 breast cancer cell transfectants expressing a cellular glutathione peroxidase cDNA and doxorubicin-resistant MCF-7 cells.

J. Doroshow, S. Akman, F. Chu, 1990, Nucleic acids research.

The proteasome inhibitor, bortezomib, in combination with gemcitabine (Gem) and carboplatin (Carbo) in advanced non-small cell lung cancer (NSCLC): Final results of a phase I California Cancer Consortium study.

J. Doroshow, D. Gandara, P. Gumerlock, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Gdac1 locus modifies spontaneous and Salmonella-induced colitis in mice deficient in either Gpx2 or Gpx1 gene.

J. Doroshow, F. Chu, T. Leto, 2013, Free radical biology & medicine.

The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.

P. Meltzer, W. Reinhold, Y. Pommier, 2013, Cancer research.

Expression of NADPH oxidase homologues and accessory genes in human cancer cell lines, tumours and adjacent normal tissues

J. Doroshow, K. Roy, A. Juhász, 2009, Free radical research.

AACR Cancer Progress Report 2016

Thomas J. Smith, S. Armstrong, R. Deberardinis, 2016, Clinical Cancer Research.

Validation of a hypoxia-inducible factor-1 alpha specimen collection procedure and quantitative enzyme-linked immunosorbent assay in solid tumor tissues.

J. Doroshow, R. Parchment, S. Kummar, 2014, Analytical biochemistry.

Phase I study of vandetanib (V) and bevacizumab (B) combination therapy evaluating the VEGF and EGF signal transduction pathways in adults with solid tumors and NHL.

G. Giaccone, J. Doroshow, J. Trepel, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biochemical modulation of fluoropyrimidines: is there an optimal (6R,S) leucovorin dose and schedule?

J. Doroshow, 1996, Journal of the National Cancer Institute.

NADPH oxidase 5 (NOX5)-induced reactive oxygen signaling modulates normoxic HIF-1α and p27

Han Liu, J. Doroshow, H. Makhlouf, 2020 .

Cediranib for metastatic alveolar soft part sarcoma.

R. Simon, P. Choyke, A. Monks, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Characterization of NADPH oxidase 5 expression in human tumors and tumor cell lines with a novel mouse monoclonal antibody.

Han Liu, J. Doroshow, S. Hewitt, 2013, Free radical biology & medicine.

The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity.

L. Rubinstein, J. Doroshow, E. Polley, 2017, Cancer research.

AACR-FDA-NCI Cancer Biomarkers Collaborative Consensus Report: Advancing the Use of Biomarkers in Cancer Drug Development

J. Doroshow, W. Hait, S. Khleif, 2010, Clinical Cancer Research.

The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line Panel.

A. Monks, C. Hose, J. Doroshow, 2018, Cancer research.

Membrane Interactions Of The Anthracycline Antibiotics

James H. Doroshow, Thomas G. Burke, Thomas R. Tritton, 1988, Photonics West - Lasers and Applications in Science and Engineering.

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

S. Ganesan, J. Doroshow, P. Borst, 2013, Cancer discovery.

Association of changes in expression of HDAC and SIRT genes after drug treatment with cancer cell line sensitivity to kinase inhibitors

L. McShane, J. Doroshow, R. Parchment, 2024, Epigenetics.

National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.

L. Staudt, E. Korn, L. McShane, 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Designing Phase 0 Cancer Clinical Trials

S. Steinberg, L. Rubinstein, J. Doroshow, 2008, Clinical Cancer Research.

Atezolizumab for Advanced Alveolar Soft Part Sarcoma.

J. Doroshow, M. Burgess, B. V. Van Tine, 2023, The New England journal of medicine.

Abstract 2416: Weekly EZN-2208 (pegylated SN-38) in combination with bevacizumab in patients with refractory solid tumors.

J. Doroshow, A. Chen, B. Turkbey, 2013 .

Systematic Establishment of Robustness and Standards in Patient-Derived Xenograft Experiments and Analysis

Anuj Srivastava, Jeffrey S. Morris, James H. Doroshow, 2020, Cancer Research.

Cancer Cell Lines Lipopolysaccharide in Human Pancreatic and γ Dual Oxidase A 2 by IFN-Synergistic Induction of Dual Oxidase 2 and Activation of TLR 4 Is Required for the Roy and

Han Liu, J. Doroshow, M. Hollingshead, 2013 .

Activation of TLR4 Is Required for the Synergistic Induction of Dual Oxidase 2 and Dual Oxidase A2 by IFN-g and Lipopolysaccharide in Human Pancreatic Cancer Cell Lines

Han Liu, J. Doroshow, M. Hollingshead, 2013 .

A phase II trial of bryostatin in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: A California cancer consortium (CCC) trial

J. Doroshow, D. Gandara, L. Leong, 2005 .

Abstract 3620: A multiplex quantitative immunofluorescence assay for DNA damage repair in response to cytotoxic treatment

Y. Pommier, J. Doroshow, R. Parchment, 2012 .

Abstract C278: Topoisomerase 1 immunoassay provides proof of target engagement by the indenoisoquinoline class of topoisomerase 1 inhibitors in canine lymphomas.

Y. Pommier, J. Doroshow, R. Parchment, 2013 .

Abstract 3366: Progress on development of multiplex panel of 15 biomarkers to support development of anticancer drugs targeting apoptosis.

D. Esposito, J. Doroshow, R. Parchment, 2013 .

A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas

L. Rubinstein, J. Doroshow, A. Chen, 2012, Clinical Cancer Research.

Abstract 1763: Quantitative gamma-H2AX immunoassay for pharmacodynamic monitoring anticancer cytotoxic agents

J. Doroshow, R. Parchment, Yiping Zhang, 2010 .

Format (2D vs 3D) and media effect target expression and response of patient-derived and standard NSCLC lines to EGFR inhibitors.

J. Doroshow, B. Teicher, G. Kaur, 2021, Cancer treatment and research communications.

Exon array analyses across the NCI-60 reveal potential regulation of TOP1 by transcription pausing at guanosine quartets in the first intron.

J. Weinstein, W. Reinhold, Y. Pommier, 2010, Cancer research.

The beginning of GPX2 and 30 years later.

J. Doroshow, F. Chu, R. Esworthy, 2022, Free radical biology & medicine.

Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors

J. Doroshow, R. Parchment, S. Kummar, 2023, Cancer chemotherapy and pharmacology.